Metronome
Metronome's platform provides real-time, usage-based billing for software companies, powering monetization for high-growth clients like OpenAI and Anthropic.
Secondary Market Price
Secondary Market Price
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections.
Sign up to Unlock the Latest DataProspect Projected Future Metronome Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Metronome's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Metronome is a billing infrastructure platform that helps software companies implement usage-based pricing. The platform provides the underlying architecture for metering, invoicing, and data management, allowing businesses to launch new products and iterate on pricing models without extensive engineering work. It is designed to handle everything from real-time consumption-based billing to complex enterprise contracts. Fast-growing companies like OpenAI and Anthropic rely on Metronome to power their monetization; for instance, the platform runs OpenAI's financial engineering and billing systems, enabling it to scale from individual developers to large enterprises. Founded in 2020 by Kevin Liu and Scott Woody, the company was created to eliminate common billing bottlenecks and help software teams transition from manual processes to modern, automated revenue operations.
The company is currently in a period of significant growth, underscored by a $50 million Series C funding round in early 2025 that brought its total funding to over $100 million. This momentum is also reflected in its recent expansion, including the opening of a new office in New York City. Metronome has also established itself as a thought leader in the space, hosting its inaugural Monetize 2025 conference with speakers from major tech companies like Salesforce and HubSpot. Looking forward, the company is positioned to be a critical infrastructure layer for the AI industry, developing features like seat-based credit pools that help companies build flexible and predictable pricing for their AI-powered products.
- Andreessen Horowitz
- General Catalyst
- NEA
- Elad Gil
- Activant Capital
- Workday Ventures
- Greyhound Capital
- William Hockey
- Co-Founder, CEO Scott Woody
- Co-Founder, Kevin Liu
Peer Group Comparison
Vs Peer Group of >$4B Startups
How Metronome measures Up
To help you manage your Metronome equity, Prospect has run the company through our machine learning model.
Prospect Rating
3x
Our rating projects that Metronome will be worth at least 3x its current value in four years.For an employee with stock options, this suggests a significant potential for growth in the value of their equity.
Exit Risk
Moderate Risk
We assigned Metronome a Moderate Risk rating—reflecting the likelihood of it not reaching a liquidity event for employees—because our analysis shows it is backed by top investors and is scaling quickly.
Funding Stage
Series C
Since Metronome is at the Series C stage, it's a well-established company focused on scaling up its business. For a potential employee, this can be the best of both worlds: you get the growth opportunities of a startup with more of the stability found at a larger company.
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Metronome worth joining?
Metronome is a Series C startup backed by top-tier investors like Andreessen Horowitz and General Catalyst, indicating strong market confidence and growth potential. To make a fully informed decision, you can use a platform like Prospect to independently evaluate the company's potential and what its equity might be worth.
What should I do with my Metronome stock?
Managing private stock like your shares in Metronome requires careful planning around valuation, tax implications, and potential liquidity events. Tools from Prospect can help you model financial scenarios and create a tax-optimized strategy for your equity.
Can you sell Metronome stock?
As Metronome is a private company, its stock isn't traded on public exchanges, but selling may be possible through private secondary market transactions. Platforms like Prospect provide data on secondary market pricing to help you understand the process and timing for such sales.
How can I find the value of my Metronome stock?
A baseline for your stock's value can be estimated from Metronome's latest valuation of $500M-$1B, but this doesn't reflect the value of your specific shares. For a more precise estimate, Prospect uses predictive models and VC-grade data to project the potential worth of your personal equity stake.
What is Metronome's equity worth?
The total equity of Metronome is valued between $500 million and $1 billion, based on its Series C funding round. The worth of an individual's holdings is a fraction of this total, determined by their specific grant, which can be analyzed with equity management tools.
What is Metronome's stock ticker symbol?
Metronome does not have a stock ticker symbol because it is a privately held company. Such symbols are only assigned to companies whose shares are listed and traded on public stock exchanges.
Can I buy or sell Metronome stock?
Since Metronome is private, its stock cannot be bought on public markets, and selling is generally limited to occasional, controlled secondary transactions. While buying is restricted to accredited investors during funding rounds, platforms like Prospect offer data to help existing stockholders navigate selling opportunities.
What is the criteria to buy or invest in Metronome stock?
The opportunity to invest in a private company like Metronome is typically limited to accredited investors and venture capital firms during official fundraising rounds. For the general public, direct investment is not an option until a company goes public through an IPO.
